Heron Therapeutics (HRTX) Assets Average (2011 - 2026)

Heron Therapeutics (HRTX) has reported Assets Average for 16 consecutive years, with $249.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 6.55% year-over-year to $249.2 million; the trailing twelve-month figure through Jun 2026 stood at $249.2 million (up 6.55% YoY), and the FY2025 full-year result was $244.5 million, up 7.32% from the prior year.
• Assets Average fell to $249.2 million in Q2 2026 per HRTX's latest filing, from $251.0 million in the prior quarter.
• Across five years, Assets Average topped out at $289.7 million in Q1 2022 and bottomed at $211.1 million in Q2 2023.
• Historically, Assets Average has averaged $239.0 million across 5 years, with a median of $235.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Assets Average tumbled 31.81% in 2022, then rose 11.21% in 2025.
• Over 5 years, Assets Average stood at $261.5 million in 2022, then dropped by 13.62% to $225.9 million in 2023, then advanced by 0.49% to $227.0 million in 2024, then rose by 11.21% to $252.4 million in 2025, then dropped by 1.26% to $249.2 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $249.2 million, $251.0 million, and $252.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.